XE
XE7C.F Cardiff Oncology Inc
- Market cap
- EUR 44.8M
- P/E
- -
- P/B
- 2.19x
- ROE
- -162.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is XE7C.F undervalued?
Graham numberThe Graham number of Cardiff Oncology Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cardiff Oncology Inc fundamental analysis
No fundamental analysis for Cardiff Oncology Inc yet.
Cardiff Oncology Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cardiff Oncology Inc
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic…
Full company profileCardiff Oncology Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cardiff Oncology Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 381K | 505K | 378K | 245K | 366K | 359K | 386K | 488K | 683K | 593K | 290K |
| Gross Profit | -1.35M | -1.31M | -219K | 245K | - | - | - | - | - | - | - |
| Operating Income | -39.4M | -23.4M | -16.4M | -16.7M | -19.1M | -28.9M | -39.9M | -45.4M | -48.7M | -49.0M | -44.9M |
| EBITDA | - | -22.6M | -15.6M | -15.9M | -18.8M | -27.8M | -39.7M | -45.0M | -47.7M | -48.1M | -44.5M |
| Net Income | -39.2M | -24.9M | -16.5M | -16.4M | -19.3M | -28.3M | -38.7M | -41.4M | -45.4M | -45.9M | -43.2M |
| EPS | - | -34 | -4.30 | -1.91 | -0.52 | -0.67 | -0.87 | -0.93 | -0.68 | -0.67 | -0.63 |
| Balance Sheet | |||||||||||
| Total Assets | 44.0M | 12.3M | 14.2M | 13.1M | 135M | 150M | 116M | 81.6M | 97.2M | 61.9M | 37.3M |
| Total Liabilities | 24.2M | 5.78M | 4.09M | 5.78M | 6.57M | 9.13M | 9.85M | 11.9M | 14.2M | 16.5M | 10.8M |
| Shareholders' Equity | 19.8M | 6.51M | 10.1M | 7.31M | 128M | 140M | 106M | 69.7M | 82.9M | 45.4M | 26.5M |
| Cash & Short-term Investments | 13.9M | 8.23M | 11.5M | 10.2M | 131M | 11.9M | 16.3M | 21.7M | 51.5M | 17.5M | 9.20M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -31.0M | -23.3M | -13.2M | -13.3M | -16.3M | -23.0M | -33.8M | -30.9M | -37.7M | -37.9M | -48.1M |
| Capital Expenditure | 823K | 101K | 5.10K | 67.6K | 211K | 205K | 1.01M | 582K | 80.0K | 44.0K | 0.00 |
| Free Cash Flow | - | -23.4M | -13.2M | -13.3M | -16.5M | -23.2M | -34.7M | -31.5M | -37.8M | -38.0M | -48.2M |
| Ratios | |||||||||||
| ROE | -198.3% | -382.8% | -163.2% | -224.5% | -15.1% | -20.1% | -36.4% | -59.4% | -54.8% | -101.0% | -162.6% |
| ROA | -89.2% | -202.7% | -116.1% | -125.4% | -14.3% | -18.9% | -33.3% | -50.8% | -46.7% | -74.1% | -115.6% |
| Net Profit Margin | -10,287.7% | -4,928.1% | -4,351.1% | -6,709.7% | -5,275.1% | -7,880.5% | -10,026.9% | -8,492.0% | -6,651.7% | -7,732.0% | -14,880.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Cardiff Oncology Inc dividends
Cardiff Oncology Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:6 on Feb 20, 2019.
Who owns Cardiff Oncology Inc
- Insiders 6.20%
- Institutions 20.53%
- Public & others 73.27%
- Shares outstanding 77.8M
- Free float 75.4M
Cardiff Oncology Inc company profile
- Company name
- Cardiff Oncology Inc
- Ticker
- XE7C.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 30
- Fiscal year end
- December
- Address
- 11055 Flintkote Avenue, San Diego, CA, United States, 92121
- Phone
- 858 952 7570
- Website
- cardiffoncology.com
About Cardiff Oncology Inc
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Cardiff Oncology Inc management
7- Dr. Mani Mohindru Ph.D.President, CEO & Director · born 1972
- Mr. Joshua Muntner BFA, M.B.A.Chief Financial Officer · born 1969
- Dr. Ajay Aggarwal M.B.A., M.D.Chief Operating Officer
- Ms. Brigitte LindsayChief Accounting Officer · born 1969
- Dr. Tod Smeal Ph.D.Chief Scientific Officer · born 1965
- Ms. Elizabeth AndersonVP of Finance & Administration
- Dr. Leila Alland M.D.Interim Chief Medical Officer · born 1962